{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:25:25Z","timestamp":1791300325172,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,3,31]],"date-time":"2015-03-31T00:00:00Z","timestamp":1427760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/bjc.2015.101","type":"journal-article","created":{"date-parts":[[2015,3,31]],"date-time":"2015-03-31T20:02:05Z","timestamp":1427832125000},"page":"1501-1509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":679,"title":["IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer"],"prefix":"10.1038","volume":"112","author":[{"given":"K","family":"Abiko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hamanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,31]]},"reference":[{"issue":"6","key":"BFbjc2015101_CR1","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","volume":"19","author":"K Abiko","year":"2013","unstructured":"Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, Yamaguchi K, Murakami R, Yamamoto A, Kharma B, Kosaka K, Konishi I (2013) PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 19 (6): 1363\u20131374.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"BFbjc2015101_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ygyno.2008.01.005","volume":"109","author":"DS Alberts","year":"2008","unstructured":"Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M (2008) Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin\/paclitaxel versus carboplatin\/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol 109 (2): 174\u2013181.","journal-title":"Gynecol Oncol"},{"issue":"7269","key":"BFbjc2015101_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Frohling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462 (7269): 108\u2013112.","journal-title":"Nature"},{"issue":"3","key":"BFbjc2015101_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ygyno.2009.11.020","volume":"116","author":"JC Barnett","year":"2010","unstructured":"Barnett JC, Bean SM, Whitaker RS, Kondoh E, Baba T, Fujii S, Marks JR, Dressman HK, Murphy SK, Berchuck A (2010) Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol 116 (3): 556\u2013562.","journal-title":"Gynecol Oncol"},{"issue":"7391","key":"BFbjc2015101_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (7391): 603\u2013607.","journal-title":"Nature"},{"issue":"3","key":"BFbjc2015101_CR6","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","volume":"64","author":"C Blank","year":"2004","unstructured":"Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF (2004) PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64 (3): 1140\u20131145.","journal-title":"Cancer Res"},{"issue":"4","key":"BFbjc2015101_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","volume":"10","author":"RL Coleman","year":"2013","unstructured":"Coleman RL, Monk BJ, Sood AK, Herzog TJ (2013) Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10 (4): 211\u2013224.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"BFbjc2015101_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (9): 942\u2013949.","journal-title":"Nat Med"},{"issue":"14","key":"BFbjc2015101_CR9","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1158\/1078-0432.CCR-06-2833","volume":"13","author":"TJ Duncan","year":"2007","unstructured":"Duncan TJ, Rolland P, Deen S, Scott IV, Liu DT, Spendlove I, Durrant LG (2007) Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Clin Cancer Res 13 (14): 4139\u20134145.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"BFbjc2015101_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (11): 991\u2013998.","journal-title":"Nat Immunol"},{"issue":"11","key":"BFbjc2015101_CR11","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","volume":"6","author":"GP Dunn","year":"2006","unstructured":"Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6 (11): 836\u2013848.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"BFbjc2015101_CR12","first-page":"2268","volume":"6","author":"RS Freedman","year":"2000","unstructured":"Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD (2000) Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 6 (6): 2268\u20132278.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"BFbjc2015101_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192 (7): 1027\u20131034.","journal-title":"J Exp Med"},{"issue":"3","key":"BFbjc2015101_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9 (3): 162\u2013174.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"BFbjc2015101_CR15","doi-asserted-by":"publisher","first-page":"e69631","DOI":"10.1371\/journal.pone.0069631","volume":"8","author":"HE Godoy","year":"2013","unstructured":"Godoy HE, Khan AN, Vethanayagam RR, Grimm MJ, Singel KL, Kolomeyevskaya N, Sexton KJ, Parameswaran A, Abrams SI, Odunsi K, Segal BH (2013) Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice. PLoS One 8 (7): e69631.","journal-title":"PLoS One"},{"issue":"3","key":"BFbjc2015101_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.clim.2011.08.013","volume":"141","author":"J Hamanishi","year":"2011","unstructured":"Hamanishi J, Mandai M, Abiko K, Matsumura N, Baba T, Yoshioka Y, Kosaka K, Konishi I (2011) The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol 141 (3): 338\u2013347.","journal-title":"Clin Immunol"},{"issue":"9","key":"BFbjc2015101_CR17","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104 (9): 3360\u20133365.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"BFbjc2015101_CR18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/stem.256","volume":"28","author":"J Hamanishi","year":"2010","unstructured":"Hamanishi J, Mandai M, Matsumura N, Baba T, Yamaguchi K, Fujii S, Konishi I (2010) Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. Stem Cells 28 (1): 164\u2013173.","journal-title":"Stem Cells"},{"issue":"5","key":"BFbjc2015101_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144 (5): 646\u2013674.","journal-title":"Cell"},{"issue":"3","key":"BFbjc2015101_CR20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","volume":"65","author":"F Hirano","year":"2005","unstructured":"Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65 (3): 1089\u20131096.","journal-title":"Cancer Res"},{"issue":"2","key":"BFbjc2015101_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","volume":"124","author":"WT Hwang","year":"2012","unstructured":"Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G (2012) Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 124 (2): 192\u2013198.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"BFbjc2015101_CR22","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.4049\/jimmunol.178.2.1122","volume":"178","author":"S Indraccolo","year":"2007","unstructured":"Indraccolo S, Pfeffer U, Minuzzo S, Esposito G, Roni V, Mandruzzato S, Ferrari N, Anfosso L, Dell\u2019Eva R, Noonan DM, Chieco-Bianchi L, Albini A, Amadori A (2007) Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol 178 (2): 1122\u20131135.","journal-title":"J Immunol"},{"issue":"19","key":"BFbjc2015101_CR23","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99 (19): 12293\u201312297.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4B","key":"BFbjc2015101_CR24","first-page":"2785","volume":"26","author":"MM Janat-Amsbury","year":"2006","unstructured":"Janat-Amsbury MM, Yockman JW, Anderson ML, Kieback DG, Kim SW (2006) Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer. Anticancer Res 26 (4B): 2785\u20132789.","journal-title":"Anticancer Res"},{"issue":"7467","key":"BFbjc2015101_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501 (7467): 346\u2013354.","journal-title":"Nature"},{"issue":"2","key":"BFbjc2015101_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ygyno.2009.11.001","volume":"116","author":"LE Kandalaft","year":"2010","unstructured":"Kandalaft LE, Singh N, Liao JB, Facciabene A, Berek JS, Powell DJ Jr, Coukos G (2010) The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol 116 (2): 222\u2013233.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"BFbjc2015101_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/molehr\/gau096","volume":"21","author":"K Kawasaki","year":"2014","unstructured":"Kawasaki K, Kondo E, Chigusa Y, Ujita M, Murakami R, Mogami H, Brown JB, Okuno Y, Konishi I (2014) Reliable pre-eclampsia pathways based on multiple independent microarray data sets. Mol Hum Reprod 21 (2): 217\u2013224.","journal-title":"Mol Hum Reprod"},{"issue":"1","key":"BFbjc2015101_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/cytob.21126","volume":"86","author":"J Kitayama","year":"2014","unstructured":"Kitayama J, Emoto S, Yamaguchi H, Ishigami H, Kamei T, Yamashita H, Seto Y, Matsuzaki K, Watanabe T (2014) Flow cytometric quantification of intraperitoneal free tumor cells in patients with peritoneal metastasis. Cytometry B 86 (1): 56\u201362.","journal-title":"Cytometry B"},{"issue":"6","key":"BFbjc2015101_CR29","first-page":"429","volume":"12","author":"S Kooi","year":"1993","unstructured":"Kooi S, Freedman RS, Rodriguez-Villanueva J, Platsoucas CD (1993) Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res 12 (6): 429\u2013437.","journal-title":"Lymphokine Cytokine Res"},{"issue":"5","key":"BFbjc2015101_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-008-0585-3","volume":"58","author":"K Li","year":"2009","unstructured":"Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S, Konishi I (2009) Clinical significance of the NKG2D ligands, MICA\/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58 (5): 641\u2013652.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"BFbjc2015101_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/modpathol.2008.187","volume":"22","author":"M Liu","year":"2009","unstructured":"Liu M, Matsumura N, Mandai M, Li K, Yagi H, Baba T, Suzuki A, Hamanishi J, Fukuhara K, Konishi I (2009) Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression. Mod Pathol 22 (3): 373\u2013384.","journal-title":"Mod Pathol"},{"issue":"6","key":"BFbjc2015101_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrc2639","volume":"9","author":"S Lob","year":"2009","unstructured":"Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P (2009) Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 9 (6): 445\u2013452.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"BFbjc2015101_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/sj.bjc.6602662","volume":"93","author":"T Maeda","year":"2005","unstructured":"Maeda T, Tashiro H, Katabuchi H, Begum M, Ohtake H, Kiyono T, Okamura H (2005) Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability. Br J Cancer 93 (1): 116\u2013123.","journal-title":"Br J Cancer"},{"issue":"4","key":"BFbjc2015101_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jhep.2006.05.007","volume":"45","author":"M Muhlbauer","year":"2006","unstructured":"Muhlbauer M, Fleck M, Schutz C, Weiss T, Froh M, Blank C, Scholmerich J, Hellerbrand C (2006) PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol 45 (4): 520\u2013528.","journal-title":"J Hepatol"},{"issue":"200","key":"BFbjc2015101_CR35","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF (2013) Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5 (200): 200ra116.","journal-title":"Sci Transl Med"},{"issue":"127","key":"BFbjc2015101_CR36","doi-asserted-by":"publisher","first-page":"127ra137","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4 (127): 127ra137.","journal-title":"Sci Transl Med"},{"issue":"2-3","key":"BFbjc2015101_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/08830185.2011.567361","volume":"30","author":"SR Thibodeaux","year":"2011","unstructured":"Thibodeaux SR, Curiel TJ (2011) Immune therapy for ovarian cancer: promise and pitfalls. Int Rev Immunol 30 (2-3): 102\u2013119.","journal-title":"Int Rev Immunol"},{"issue":"26","key":"BFbjc2015101_CR38","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (26): 2443\u20132454.","journal-title":"N Engl J Med"},{"issue":"6","key":"BFbjc2015101_CR39","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/ndt\/gfl818","volume":"22","author":"Y Waeckerle-Men","year":"2007","unstructured":"Waeckerle-Men Y, Starke A, Wuthrich RP (2007) PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells. Nephrol Dial Transplant 22 (6): 1527\u20131536.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"BFbjc2015101_CR40","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","volume":"183","author":"TL Walunas","year":"1996","unstructured":"Walunas TL, Bakker CY, Bluestone JA (1996) CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183 (6): 2541\u20132550.","journal-title":"J Exp Med"},{"issue":"6","key":"BFbjc2015101_CR41","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1054\/bjoc.1999.1053","volume":"82","author":"GH Windbichler","year":"2000","unstructured":"Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Muller-Holzner E, Marth C (2000) Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82 (6): 1138\u20131144.","journal-title":"Br J Cancer"},{"issue":"2","key":"BFbjc2015101_CR42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2): 122\u2013133.","journal-title":"N Engl J Med"},{"issue":"1","key":"BFbjc2015101_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/ijc.25961","volume":"130","author":"S Yamamura","year":"2012","unstructured":"Yamamura S, Matsumura N, Mandai M, Huang Z, Oura T, Baba T, Hamanishi J, Yamaguchi K, Kang HS, Okamoto T, Abiko K, Mori S, Murphy SK, Konishi I (2012) The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer 130 (1): 20\u201328.","journal-title":"Int J Cancer"},{"key":"BFbjc2015101_CR44","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4: 2612.","journal-title":"Nat Commun"},{"issue":"19","key":"BFbjc2015101_CR45","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","volume":"17","author":"MR Zaidi","year":"2011","unstructured":"Zaidi MR, Merlino G (2011) The two faces of interferon-gamma in cancer. Clin Cancer Res 17 (19): 6118\u20136124.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"BFbjc2015101_CR46","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"QW Zhang","year":"2012","unstructured":"Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 7 (12): e50946.","journal-title":"PLoS One"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2015101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2015101","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2015101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T03:09:14Z","timestamp":1691550554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2015101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,31]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFbjc2015101"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2015.101","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,31]]},"assertion":[{"value":"22 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2015","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}